Zacks: Check Cap Ltd (CHEK) Given $14.00 Average Price Target by Brokerages

Check Cap Ltd (NASDAQ:CHEK) has been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.

Brokers have set a 12 month consensus target price of $14.00 for the company and are expecting that the company will post ($0.54) EPS for the current quarter, according to Zacks. Zacks has also assigned Check Cap an industry rank of 69 out of 257 based on the ratings given to related companies.

Separately, HC Wainwright set a $14.00 price objective on shares of Check Cap and gave the company a “buy” rating in a research note on Tuesday, November 6th.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP purchased a new stake in Check Cap during the 3rd quarter valued at about $141,000. Fosun International Ltd purchased a new stake in Check Cap during the 2nd quarter valued at about $517,000. Finally, Renaissance Technologies LLC purchased a new stake in Check Cap during the 2nd quarter valued at about $524,000. 1.55% of the stock is owned by institutional investors.

Shares of CHEK stock traded up $0.09 on Friday, reaching $3.22. 9,600 shares of the company were exchanged, compared to its average volume of 263,679. Check Cap has a 1 year low of $3.08 and a 1 year high of $19.78.

Check Cap (NASDAQ:CHEK) last released its earnings results on Monday, November 5th. The medical research company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.03. As a group, equities analysts anticipate that Check Cap will post -2.57 EPS for the current fiscal year.

Check Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.

Read More: What is a Call Option?

Get a free copy of the Zacks research report on Check Cap (CHEK)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with's FREE daily email newsletter.

Leave a Reply